Article

Single-Boosted Protease Inhibitor versus Double-Boosted Protease Inhibitors for the Salvage Therapy in HIV-Infected Patients.

Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, .
Journal of the International Association of Physicians in AIDS Care (JIAPAC) 01/2011; 10(2):105-10. DOI:10.1177/1545109710383335
Source: PubMed

ABSTRACT Objective: To compare treatment outcomes between the regimens of single-boosted protease inhibitor (PI) and double-boosted PIs for the salvage therapy in patients who failed nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens.
A total of 64 patients from 2 cohorts, 40 in twice daily ritonavir-boosted lopinavir (LPV/r) at 400/100 mg plus lamivudine (3TC) and 24 in once daily ritonavir-boosted atazanavir and saquinavir (ATV/SQV/r) at 300/1600/100 mg/d, were studied.
At 48 weeks, 30 (75%) patients in LPV/r group and 20 (83%) patients in ATV/SQV/r group achieved HIV-1 RNA at <400 copies/mL (P = .790). In all, 24 (60%) and 16 (67%) achieved HIV-1 RNA at <50 copies/mL (P = .541). Low-level viral rebound (51-400 copies/mL) was found in 6 (15%) in LPV/r group and 4 (17%) in ATV/SQV/r group (P = 1.000). Medians CD4 counts were 336 cells/mm(3) and 330 cells/mm(3) in the corresponding groups (P = 0.937).
No additional benefit is found with double-boosted PIs compared to single-boosted PI in terms of treatment responses in HIV-infected patients failing NNRTI-based regimen.

0 0
 · 
0 Bookmarks
 · 
51 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

2 cohorts
 
64 patients
 
ATV/SQV/r
 
ATV/SQV/r group
 
corresponding groups
 
double-boosted PIs
 
HIV-1 RNA
 
HIV-infected patients
 
LPV/r
 
LPV/r group
 
NNRTI)-based regimens
 
NNRTI-based regimen
 
nonnucleoside reverse transcriptase inhibitor
 
patients
 
regimens
 
salvage therapy
 
single-boosted PI
 
single-boosted protease inhibitor
 
treatment outcomes
 
treatment responses